Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (2)
  • Antibiotic
    (1)
  • Antifungal
    (1)
  • Apoptosis
    (1)
  • Bcl-2 Family
    (1)
  • IRE1
    (1)
  • Somatostatin
    (1)
  • c-Myc
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

mrna cleavage

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    3
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    3
    TargetMol | Recombinant_Protein
Toyocamycin
Vengicide
T17143606-58-6
Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycetes, functioning as an XBP1 inhibitor and inhibiting IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM), and induces apoptosis.
  • $39
In Stock
Size
QTY
Cortistatin-29 (rat) (trifluoroacetate salt)
T356631815618-17-7
Cortistatin-29 is a neuropeptide that is structurally similar to somatostatin-28. It is produced by cleavage of preprocortistatin to procortistatin, which is cleaved at dibasic amino acids to form cortistatin-29 and cortistatin-14 as well as other partial cleavage products. Cortistatin mRNA is expressed in the human brain and in interneurons of the rat hippocampus and cerebral cortex. Cortistatin-29 binds to somatostatin (SST) receptors with IC50 values of 2.8, 7.1, 0.2, 3, and 13.7 nM for SST1-5, respectively. Cortistatin-29 is found at similar levels as cortistatin-14 in mouse AtT20 cells but is secreted at a lower level. Cortistatin-29 corresponds to residues 85-112 of the rat peptide sequence.
  • Inquiry Price
Inquiry
Size
QTY
AZ5576 racemate
T709531333468-05-5
AZ5576 racemate is a racemic mixture of AZ5576 isomers. AZ5576 is a potent, highly selective, and orally bioavailable inhibitor of Cdk9 that inhibits Cdk9 enzyme activity with an IC50 <5nM and decreases phosphorlyation of Ser2-RNAPII in cells with an IC50 of 96nM. In the MLL-fusion containing acute myeloid leukemia (AML) line, MV411, short-term treatment with AZ5576 led to a rapid dose-dependent decrease in pSer2-RNAPII with concomitant loss of Mcl1 mRNA and protein, resulting in the cleavage and activation of caspase 3 and loss of cell viability.
  • $1,520
1-2 weeks
Size
QTY